Repeat-dose dexamethasone to prevent pain relapse after total knee arthroplasty in high-pain-response patients: A randomised, double-blind, placebo-controlled superiority trial
- PMID: 40364780
- DOI: 10.1097/EJA.0000000000002189
Repeat-dose dexamethasone to prevent pain relapse after total knee arthroplasty in high-pain-response patients: A randomised, double-blind, placebo-controlled superiority trial
Abstract
Background: Peri-operative glucocorticoids reduce pain after total knee arthroplasty, with evidence suggesting potential benefits of increased dosing in specific patient groups. However, the impact of repeat-dose glucocorticoids has not been studied in high-pain-response patients receiving pre-operative high-dose glucocorticoids.
Objective: To investigate the effect on pain of an oral dose of dexamethasone after total knee arthroplasty in selected high-pain-response patients who had received a pre-operative high dose of intravenous dexamethasone (1 mg kg -1 ).
Design: Randomised, double-blind, placebo-controlled superiority study.
Setting: A multicentre study conducted at two major arthroplasty centres in Denmark from November 2021 to March 2024.
Patients: One hundred and ten patients undergoing total knee arthroplasty who had received multimodal analgesia including pre-operative intravenous dexamethasone 1 mg kg -1 . Selection criteria included a Pain Catastrophising Scale score greater than 20 and moderate-to-severe pain (VAS >30) during walking 24 h postoperatively.
Intervention: Patients were randomised to either oral dexamethasone 24 mg or placebo on postoperative day 1.
Main outcome measures: The primary outcome was the proportion of patients experiencing moderate-to-severe pain during walking at 48 h postoperatively. Secondary outcomes included pain scores at various time points within 1 week postoperatively, rescue analgesics, quality of sleep, length of hospital stay and morbidity with follow-up at 30 days.
Results: At 48 h postoperatively, 65% of patients in the dexamethasone group and 79% in the placebo group reported moderate-to-severe pain during walking: odds ratio 0.48 [95% confidence interval (CI), 0.20 to 1.16]; P = 0.100. The mean ± SD Visual Analogue Scale (VAS) at 48 h during walking was 43 ± 21 in the dexamethasone group and 51 ± 22 in the placebo group ( P = 0.051). There were no differences between the groups regarding secondary pain outcomes or the use of rescue analgesics.
Conclusion: The administration of a high oral dose of dexamethasone following an initial pre-operative dose of 1 mg kg -1 intravenously in selected high-pain-response patients had no effect on postoperative pain following total knee arthroplasty.
Trial registration: ClinicalTrials.gov identifier NCT05563155.
Copyright © 2025 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.
References
-
- Aasvang EK, Luna IE, Kehlet H. Challenges in postdischarge function and recovery: the case of fast-track hip and knee arthroplasty. Br J Anaesth 2015; 115:861–866.
-
- Kehlet H, Joshi GP. The systematic review/meta-analysis epidemic: a tale of glucocorticoid therapy in total knee arthroplasty. Anaesthesia 2020; 75:856–860.
-
- Springborg AH, Visby L, Kehlet H, et al. Psychological predictors of acute postoperative pain after total knee and hip arthroplasty: a systematic review. Acta Anaesthesiol Scand 2023; 67:1322–1337.
-
- Køppen KS, Gasbjerg KS, Andersen JH, et al. Systemic glucocorticoids as an adjunct to treatment of postoperative pain after total hip and knee arthroplasty: a systematic review with meta-analysis and trial sequential analysis. Eur J Anaesthesiol 2023; 40:155–170.
-
- Lex JR, Edwards TC, Packer TW, et al. Perioperative systemic dexamethasone reduces length of stay in total joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty 2021; 36:1168–1186.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
